According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “
MSTX has been the topic of several other reports. Maxim Group set a $5.00 price objective on Mast Therapeutics and gave the company a buy rating in a research report on Thursday, September 8th. Laidlaw cut Mast Therapeutics from a buy rating to a neutral rating in a research report on Wednesday, September 21st. Cowen and Company cut Mast Therapeutics from an outperform rating to a market perform rating in a research report on Friday, September 23rd. Roth Capital reissued a buy rating and issued a $2.00 target price on shares of Mast Therapeutics in a report on Friday, July 15th. Finally, Canaccord Genuity reissued a buy rating and issued a $3.00 target price on shares of Mast Therapeutics in a report on Thursday, July 28th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Mast Therapeutics has an average rating of Hold and a consensus target price of $2.07.
Shares of Mast Therapeutics (NASDAQ:MSTX) opened at 0.085 on Wednesday. The firm’s 50-day moving average is $0.31 and its 200 day moving average is $0.36. Mast Therapeutics has a 12-month low of $0.08 and a 12-month high of $0.71. The stock’s market capitalization is $18.00 million.
Mast Therapeutics (NASDAQ:MSTX) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts forecast that Mast Therapeutics will post ($0.19) EPS for the current fiscal year.
A hedge fund recently raised its stake in Mast Therapeutics stock. Vanguard Group Inc. increased its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent SEC filing.
About Mast Therapeutics
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.